الصفحة الرئيسية>>Signaling Pathways>> Apoptosis>> Other Apoptosis>>Talampanel

Talampanel (Synonyms: GYKI 53773, LY 300164)

رقم الكتالوجGC19346

Talampanel (LY300164) هو مضاد لمستقبلات ألفا-أمينو-3-هيدروكسي-5-ميثيل-4-إيزوكسازوليبروبيونات (AMPA) عن طريق الفم والانتقائية مع نشاط مضاد للتشنج

Products are for research use only. Not for human use. We do not sell to patients.

Talampanel التركيب الكيميائي

Cas No.: 161832-65-1

الحجم السعر المخزون الكميّة
5mg
62٫00
متوفر
10mg
93٫00
متوفر
50mg
324٫00
متوفر
100mg
508٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Talampanel is a potent and selective AMPA-receptor antagonist, is a potential new antiepileptic drug (AED). Target: AMPA [1]in vitro: Talampanel is a glutamate receptor inhibitor with anti-seizure activity.in vivo: Talampanel reduces motoneuronal calcium in a mouse model of ALS, but its effi cacy declines as the disease progresses, suggesting that medication initiation in the earlier stages of the disease might be more effective. [2]

References:
[1]. Langan YM, et al. Talampanel, a new antiepileptic drug: single- and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy. Epilepsia. 2003 Jan;44(1):46-53.
[2]. Paizs M, et al. Talampanel reduces the level of motoneuronal calcium in transgenic mutant SOD1 mice only if applied presymptomatically. Amyotroph Lateral Scler. 2011 Sep;12(5):340-344.

مراجعات

Review for Talampanel

Average Rating: 5 ★★★★★ (Based on Reviews and 27 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Talampanel

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.